NO3037424T3 - - Google Patents

Info

Publication number
NO3037424T3
NO3037424T3 NO14837210A NO14837210A NO3037424T3 NO 3037424 T3 NO3037424 T3 NO 3037424T3 NO 14837210 A NO14837210 A NO 14837210A NO 14837210 A NO14837210 A NO 14837210A NO 3037424 T3 NO3037424 T3 NO 3037424T3
Authority
NO
Norway
Application number
NO14837210A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO3037424T3 publication Critical patent/NO3037424T3/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
NO14837210A 2013-08-22 2014-08-22 NO3037424T3 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013172746 2013-08-22
PCT/JP2014/071951 WO2015025936A1 (ja) 2013-08-22 2014-08-22 新規キノリン置換化合物

Publications (1)

Publication Number Publication Date
NO3037424T3 true NO3037424T3 (hu) 2018-04-07

Family

ID=52483707

Family Applications (1)

Application Number Title Priority Date Filing Date
NO14837210A NO3037424T3 (hu) 2013-08-22 2014-08-22

Country Status (22)

Country Link
US (2) US9650386B2 (hu)
EP (1) EP3037424B1 (hu)
JP (1) JP6161705B2 (hu)
KR (1) KR101906688B1 (hu)
CN (1) CN105683195B (hu)
AU (1) AU2014309788B2 (hu)
BR (1) BR112016003247B1 (hu)
CA (1) CA2922077C (hu)
DK (1) DK3037424T3 (hu)
ES (1) ES2656712T3 (hu)
HK (1) HK1222393A1 (hu)
HU (1) HUE034807T2 (hu)
MX (1) MX370808B (hu)
MY (1) MY182891A (hu)
NO (1) NO3037424T3 (hu)
PH (1) PH12016500225A1 (hu)
PL (1) PL3037424T3 (hu)
PT (1) PT3037424T (hu)
RU (1) RU2689158C2 (hu)
SG (1) SG11201600759XA (hu)
TW (1) TWI603971B (hu)
WO (1) WO2015025936A1 (hu)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE034807T2 (hu) * 2013-08-22 2018-02-28 Taiho Pharmaceutical Co Ltd Új kinolin-szubsztituált vegyület
JOP20190073A1 (ar) * 2016-10-31 2019-04-07 Taiho Pharmaceutical Co Ltd مثبط انتقائي لمستقبل عامل نمو بشروي (egfr) لطافر إدخال exon 20
AU2017363199B2 (en) * 2016-11-17 2023-08-17 Board Of Regents, The University Of Texas System Compounds with anti-tumor activity against cancer cells bearing EGFR or HER2 exon 20 mutations
CN108101905A (zh) * 2016-11-24 2018-06-01 中国科学院上海药物研究所 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途
FR3068971B1 (fr) * 2017-07-12 2019-08-30 Protneteomix Acides 5-{4-allyl-5-[2-(4-alcoxyphenyl)quinolein-4-yl]-4h-1,2,4-triazole-3-ylsulphanylmethyl}furan-2-carboxyliques dans le traitement du cancer
JOP20200044A1 (ar) 2017-09-01 2020-02-26 Taiho Pharmaceutical Co Ltd مثبط انتقائي egfr طافر exon 18 و/أو exon 21
SG11202106986VA (en) * 2018-12-28 2021-07-29 Taiho Pharmaceutical Co Ltd L718 and/or l792 mutant treatment-resistant egfr inhibitor
SG11202110376XA (en) 2019-03-19 2021-10-28 Voronoi Inc Heteroaryl derivative, method for producing the same, and pharmaceutical composition comprising same as effective component
CN115181104A (zh) * 2019-09-29 2022-10-14 深圳市塔吉瑞生物医药有限公司 取代的稠合三环衍生物及其组合物及用途
WO2021127456A1 (en) 2019-12-19 2021-06-24 Rain Therapeutics Inc. Methods of inhibiting epidermal growth factor receptor proteins
CN113861195B (zh) * 2020-06-30 2022-11-18 上海和誉生物医药科技有限公司 一种多稠环egfr抑制剂及其制备方法和应用
WO2022007841A1 (zh) * 2020-07-09 2022-01-13 上海和誉生物医药科技有限公司 一种egfr抑制剂、其制备方法和在药学上的应用
WO2022055895A1 (en) * 2020-09-08 2022-03-17 Cullinan Pearl Corp. Treatment regimens for exon-20 insertion mutant egfr cancers
WO2022121967A1 (zh) * 2020-12-09 2022-06-16 南京药石科技股份有限公司 Egfr酪氨酸激酶抑制剂及其用途
WO2022265950A1 (en) 2021-06-15 2022-12-22 Genentech, Inc. Egfr inhibitor and perk activator in combination therapy and their use for treating cancer
CN115707704A (zh) * 2021-08-20 2023-02-21 中山医诺维申新药研发有限公司 氘代稠合三环类化合物及其组合物和用途
CN115785107A (zh) * 2022-12-15 2023-03-14 南京雷正医药科技有限公司 一种取代8,9-二氢嘧啶并[5,4-b]吲嗪类化合物、药物组合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW440562B (en) 1994-05-20 2001-06-16 Taiho Pharmaceutical Co Ltd Condensed-indan derivative and pharmaceutically acceptable salts thereof
AU2006227447A1 (en) * 2005-03-17 2006-09-28 Novartis Ag N- [3- (1-amin0-5, 6, 7, 8-tetrahydro-2 , 4, 4b-triazafluoren-9-yl)-phenyl] benzamides as tyrosine/threonine kinase inhibitors, in particular b-RAF kinase
WO2011004610A1 (ja) 2009-07-10 2011-01-13 大鵬薬品工業株式会社 アザ二環式化合物又はその塩
US7718662B1 (en) * 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
MX2013007938A (es) 2011-01-07 2013-11-01 Taiho Pharmaceutical Co Ltd Compuesto biciclico novedoso o sal del mismo.
WO2013047813A1 (ja) * 2011-09-30 2013-04-04 大鵬薬品工業株式会社 1,2,4-トリアジン-6-カルボキサミド誘導体
TWI594986B (zh) 2011-12-28 2017-08-11 Taiho Pharmaceutical Co Ltd Antineoplastic agent effect enhancer
TW201336847A (zh) * 2012-02-07 2013-09-16 Taiho Pharmaceutical Co Ltd 喹啉基吡咯并嘧啶化合物或其鹽
ES2580530T3 (es) 2012-02-23 2016-08-24 Taiho Pharmaceutical Co., Ltd. Compuesto con anillo fusionado de quinolilpirrolopirimidilo o sal del mismo
KR20150119401A (ko) * 2013-02-22 2015-10-23 다이호야쿠힌고교 가부시키가이샤 3환성 화합물의 제조 방법 및 상기 제조 방법에 의해 얻을 수 있는 3환성 화합물
HUE034807T2 (hu) * 2013-08-22 2018-02-28 Taiho Pharmaceutical Co Ltd Új kinolin-szubsztituált vegyület

Also Published As

Publication number Publication date
RU2689158C2 (ru) 2019-05-24
RU2016110096A (ru) 2017-09-27
EP3037424A1 (en) 2016-06-29
AU2014309788A1 (en) 2016-03-10
PH12016500225B1 (en) 2016-05-02
CA2922077C (en) 2018-06-26
US9650386B2 (en) 2017-05-16
PT3037424T (pt) 2017-12-18
DK3037424T3 (en) 2017-12-11
TW201542547A (zh) 2015-11-16
WO2015025936A1 (ja) 2015-02-26
CA2922077A1 (en) 2015-02-26
KR20160043114A (ko) 2016-04-20
SG11201600759XA (en) 2016-03-30
KR101906688B1 (ko) 2018-10-10
PH12016500225A1 (en) 2016-05-02
US20160194332A1 (en) 2016-07-07
MX370808B (es) 2020-01-07
JP6161705B2 (ja) 2017-07-12
EP3037424A4 (en) 2017-01-25
RU2016110096A3 (hu) 2018-06-18
ES2656712T3 (es) 2018-02-28
MY182891A (en) 2021-02-05
RU2019114688A (ru) 2020-07-29
US9758526B2 (en) 2017-09-12
US20170101414A1 (en) 2017-04-13
HUE034807T2 (hu) 2018-02-28
MX2016002125A (es) 2016-06-28
JPWO2015025936A1 (ja) 2017-03-02
PL3037424T3 (pl) 2018-03-30
EP3037424B1 (en) 2017-11-08
HK1222393A1 (zh) 2017-06-30
AU2014309788B2 (en) 2017-02-16
CN105683195A (zh) 2016-06-15
BR112016003247B1 (pt) 2022-05-10
TWI603971B (zh) 2017-11-01
CN105683195B (zh) 2017-11-10
BR112016003247A2 (hu) 2017-08-01

Similar Documents

Publication Publication Date Title
AP2016009275A0 (hu)
BR112015007533A2 (hu)
BR102016010778A2 (hu)
BR112016011851A2 (hu)
BR112014017733A2 (hu)
BR112014017739A2 (hu)
BR112014018502A2 (hu)
BR112014019326A2 (hu)
BR112014018516A2 (hu)
BR112014018480A2 (hu)
BR112014017765A2 (hu)
BR112014017855A2 (hu)
BR112014017669A2 (hu)
BR112014021878A2 (hu)
NO3037424T3 (hu)
BR112014018468A2 (hu)
BR112014018207A2 (hu)
BR112014017901A2 (hu)
BR112014019204A2 (hu)
BR112014017722A2 (hu)
BR112014018578A2 (hu)
BR112014018483A2 (hu)
BR112014017653A2 (hu)
BR112014017794A2 (hu)
BR112014017601A2 (hu)